On the 22nd, NTL Healthcare, the medical AI company,

announced its participation as a member of the public-private partnership 'CancerX,'

formed for the US government's Cancer Moonshot project.

 

 

The Cancer Moonshot is a declaration by President Joe Biden during his vice presidency,

aiming to boost innovation in the fight against cancer.

It is an innovative cancer moonshot project that pours in "one billion dollars",

comparable to the challenge of landing on the moon.

 

 

CancerX is an officially approved organization by the White House,

co-hosted by the Moffitt Cancer Center, the leading cancer research institute in the United States,

and the Digital Medicine Society. In addition to NTL Healthcare, other members include big pharmaceutical companies

such as Johnson & Johnson, AstraZeneca, Genentech, as well as leading global cancer institutions,

digital healthcare companies, and IT companies such as Intel and Amazon Web Services.

NTL Healthcare joined CancerX, recognized for its cervical cancer screening system.

 

 

Participating companies, including NTL, receive funding

from the US government to conduct various evidence-based research for cancer moonshot.

Along with policy support, massive investments totaling 1.8 billion dollars are being made,

introducing innovative technologies in cancer treatment and diagnosis.

The long-term goal is to cut the death rate from cancer by at least 50% over the next 25 years.

 

 

CancerX was initially announced in 2016 but was delayed due to the COVID-19 pandemic.

After the inauguration of the Biden administration, efforts to resume CancerX have begun in earnest.

The Biden government has set 8 specific tasks for CancerX, including cancer prevention, early detection,

development of immunotherapies, data collection and sharing, and optimization of cancer treatment healthcare systems.

 

 

NTL Healthcare, which has already exported AI cervical cancer screening systems to countries

such as Vietnam, Thailand, and Mongolia, is expected to contribute to the fields of early cancer detection

and immunotherapy development, which CancerX focuses on.

Also, NTL Healthcare plans to expand its presence in the global market, starting with its participation in CancerX.

 

 

NTL Healthcare is a femtech company that aims to improve the quality of life for women

by providing various screening services, including cervical cancer.

They have developed an AI cervical cancer screening system called 'CerviCARE AI.'

 

 

Particularly, 'CerviCARE AI' is an innovative cervical cancer screening system

based on cervical imaging data accumulated over 28 years of screening services provided by NTL.

It can analyze cervical cancer test results as normal or abnormal,

supporting clinical decision for healthcare professionals in determining the necessary treatment direction.